- Home
- SYRE vs CHWY Comparison
SYRE vs CHWY Comparison
Compare SYRE & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | CHWY |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.5B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SYRE | CHWY |
|---|---|---|
| Price | $90.96 | $20.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | ★ $85.08 | $43.52 |
| AVG Volume (30 Days) | 1.1M | ★ 8.5M |
| Earning Date | 05-08-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $12,601,500,000.00 |
| Revenue This Year | N/A | $10.70 |
| Revenue Next Year | N/A | $7.84 |
| P/E Ratio | ★ N/A | $49.76 |
| Revenue Growth | N/A | ★ 6.24 |
| 52 Week Low | $14.51 | $17.40 |
| 52 Week High | $110.18 | $40.55 |
Technical Indicators
Market Signals| Indicator | SYRE | CHWY |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 38.21 |
| Support Level | $82.83 | $19.78 |
| Resistance Level | $92.10 | $22.28 |
| Average True Range (ATR) | 3.85 | 0.98 |
| MACD | 0.24 | -0.30 |
| Stochastic Oscillator | 56.93 | 18.03 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About CHWY Chewy Inc.
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.